B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bergenbio ASA
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Net Issuance of Common Stock
kr147.7m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Net Issuance of Common Stock
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Net Issuance of Common Stock
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Net Issuance of Common Stock
kr2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-25%
N
Nykode Therapeutics ASA
OSE:NYKD
Net Issuance of Common Stock
$44.9m
CAGR 3-Years
1 044%
CAGR 5-Years
12%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Net Issuance of Common Stock
kr447k
CAGR 3-Years
-91%
CAGR 5-Years
-71%
CAGR 10-Years
-34%
No Stocks Found

Bergenbio ASA
Glance View

Market Cap
461.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Net Issuance of Common Stock?
Net Issuance of Common Stock
147.7m NOK

Based on the financial report for Sep 30, 2024, Bergenbio ASA's Net Issuance of Common Stock amounts to 147.7m NOK.

What is Bergenbio ASA's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
14%

Over the last year, the Net Issuance of Common Stock growth was -42%.

Back to Top